News/Interviews
New FDA-Approved Pergolide Product
March 20, 2012
A new FDA-approved Pergolide product offers options in the management of clinical signs associated with pituitary pars intermedia dysfunction (PPID), also known as equine Cushing's disease.
Related Articles
- Ask the Vet LIVE: Equine Cushing's Disease (PPID), Sept. 18
- Seasonal Effects on Texas Cushing's Test Results (AAEP 2011)
- Researchers Evaluate Endocrinopathic Laminitis Prevalence
- Researchers Evaluate Steps for Diagnosing Cushing's Disease
- First Equine Endocrinology Summit Held
- Pergolide Remains Treatment of Choice for PPID
- Preventing Laminitis in At-Risk Horses
- Understand PPID to Help Treat Endocrinopathic Laminitis
- Potential Biomarker for Equine Cushing's Identified
- Equine Cushing's in an Old Mare









